Summary The effects of a combination of aminoglutethimide (AG) 1,000mg daily and 4-hydroxyandrostenedione (40HA) 500 mg i.m. weekly on peripheral aromatase activity as measured by in vivo radioisotopic tracer methodology and serum oestrogen suppression were investigated in ten post-menopausal women with advanced breast cancer. Patients were treated for a minimum of 4 weeks with 40HA before addition of AG for a minimum of 6 weeks. Aromatase inhibition was found to be nearly identical in the two treatment situations (92.5 ± 4.7% and 93.8 ± 3.8% respectively). There was no further significant suppression of plasma oestradiol or plasma oestrone levels when AG was added to 40HA treatment (mean decrease of 7.6 ± 12.1% and 2.8 ± 12.0% respectively). In contrast, adding AG caused a further suppression of plasma oestrone sulphate (Oe,S) compared with 40HA monotherapy (mean suppression of 35.2 ± 9.1%, P <0.025). This effect on Oe,S may be due to an influence of AG on oestrogen metabolism.
Aromatase inhibition is an established mode of treatment for advanced post-menopausal breast cancer. The first-generation aromatase inhibitor, aminoglutethimide (AG), has been in clinical use for two decades (L0nning & Kvinnsland, 1988) , and currently several new aromatase inhibitors are going through phase I-III trials (Lipton et al., 1990; Stein et al., 1990; Evans et al., 1992; Iveson et al., 1993) .
Aromatase inhibitors act by inhibiting the peripheral conversion of circulating androgens into oestrogens. The major oestrogen production pathway in post-menopausal women is aromatisation of circulating androstenedione (A) into oestrone (Oel), while aromatisation of circulating testosterone (T) into oestradiol (Oe2) is a minor pathway (Figure 1 ). Direct oestrogen secretion by the ovaries and adrenal glands does not contribute significantly to oestrogen production, and so far no other oestrogen production pathway has been identified in post-menopausal women (L0nning et al., 1990) .
Several aromatase inhibitors, such as aminoglutethimide, lentaron (4-hydroxyandrostenedione, 40HA) and fadrozole (CGS 16949A), have been found to inhibit in vivo conversion of A into Oel by >90% as measured by tracer techniques (Santen et al., 1978; Dowsett et al., 1985; Reed et al., 1990; L0nning et al., 1991; Jones et al., 1992) . On the other hand, plasma and urine oestrogens have consistently been reported to be sustained at about 30-40% of their control values in patients on treatment with these drugs (Santen et al., 1982 Dowsett et al., 1989 Dowsett et al., , 1990 Johannessen et al., 1993) . Whether this discrepancy is due to technical artefacts in the radioimmunoassays or alternative oestrogen sources in postmenopausal women has not been resolved.
There have been different approaches to explore this phenomenon further. In a pilot study we investigated the effect of adding AG 1,000 mg daily to patients receiving treatment with 40HA given in the recommended schedule of 250 mg i.m. every 2 weeks. Combined treatment caused a further suppression of plasma oestrogens compared with treatment with 40HA single-drug therapy, and two of the seven patients responded clinically (L0nning et al., 1992 Drug schedule Based on previous endocrine data, response rates and local side-effects, the recommended dose of 40HA is 250 mg i.m. every 2 weeks (Dowsett et al., 1987 (Dowsett et al., , 1989 . Recent results suggest that a dose of 500 mg every 2 weeks causes increased aromatase inhibition . The primary aim of this study was to assess the effects of AG in patients already having maximal aromatase inhibition on treatment with 40HA, and therefore a drug schedule of 40HA injections 500 mg weekly (the maximum dose regimen for clinical treatment) was used. AG may be used at different doses varying from 250 mg to 1,000 mg daily (L0nning & Kvinnsland, 1988) . While AG may inhibit aromatase effectively at 250 mg daily (Dowsett et al., 1985) , evidence suggests that its efficacy as an enzyme inducer and its influence on oestrogen metabolism is dose dependent, with a dose of 1,000 mg daily necessary to achieve a maximal effect (L0nning et al., 1986a,b (Table III) .
Discussion
Pretreatment aromatisation rates and oestrogen values were both within previously published ranges L0nning et al., 1991; MacNeill et al., 1992) . Aromatase inhibition and oestrogen suppression for 40HA 500 mg per week are in the same range as previously found for 40HA 500 mg every 2 weeks (Dowsett et al., 1987 (Dowsett et al., , 1989 Jones et al., 1992 This investigation was designed to explore further the influence of 40HA and AG on oestrogen disposition. In a previous trial we showed that giving AG 1,000 mg daily to patients being treated with 40HA further enhanced plasma oestrogen suppression (L0nning et al., 1992) . There may be several explanations for this finding. While the dose of 40HA used in that investigation (250 mg every 2 weeks) is the dose recommended for clinical treatment and is found to suppress plasma oestrogens effectively (Dowsett et al., 1987 (Dowsett et al., , 1989 , recent findings from our group suggest that higher doses (such as 500 mg every 2 weeks) may cause a somewhat better aromatase inhibition in vivo . Thus, to address the possibility that our previous findings may have (%)   1  26  46  -76  33  23  29  20  6  69  2  67  39  41  29  38  -28  68  60  12  3  39  23  42  41  25  39  70  43  38  4  52  45  13  42  47  -11  27  15  45  5  19  16  16  46  18  60  30  11  65  6  23  17  23  23 (L0nning et al., 1992) . In the present investigation, we found that AG produced no further suppression of plasma Oel and Oe2 but a further suppression of plasma Oe,S by a mean of 32.9% when added to 40HA given as a 'high-dose drug schedule' of 500 mg weekly. In addition, this study revealed that AG caused no further enhancement of aromatase inhibition when added to this 'high-dose' 40HA schedule. In our opinion, the findings of the two studies are in accordance with each other and may be interpreted as follows. As discussed above, 40HA given in a drug schedule of 250 mg every 2 weeks causes incomplete aromatase inhibition compared with a dose of 500 mg . This submaximal aromatase inhibition may be further enhanced either by increasing the 40HA dose or by adding another aromatase inhibitor, such as AG. However, if 40HA is given at a dose of 500 mg per week, adding AG may not significantly enhance aromatase inhibition and would not be expected to have any significant influence on plasma Oel and Oe2. In contrast, adding AG to this high-dose 40HA regimen probably further suppresses plasma Oe1S by enhancing plasma OejS metabolism (L0nning et al., 1987, 1989 (Lien et al., 1990; Lundgren et al., 1990 ). We did not have the opportunity to evaluate plasma levels of 40HA in this investigation, and so we cannot exclude the possibility that AG may enhance 40HA metabolism and reduce 40HA plasma levels. On the other hand, it should be recalled that the dose of 40HA used in this investigation (500mg per week) is twice the dose previously reported to cause optimal aromatase inhibition . Thus, even if a drug interaction cannot be excluded, it is questionable whether it would be of clinical significance with the high doses of 40HA used in this investigation.
Conclusion
In conclusion, this work suggests that AG causes enhanced suppression of Oel and Oe2 in patients on treatment with 40HA only when the dose of 40HA is such that it achieves submaximal aromatase inhibition. However, further suppression of Oe1S may be achieved by the specific effects of AG on the metabolism of Oe1S. It has been suggested that Oe1S may be an important precursor to intracellular oestrogens (Santner et al., 1984) , but the absolute contribution of this hormone to intracellular oestrogen concentrations is not known.
If plasma Oe1S is a major contributor to intracellular oestrogens, the possibility exists that this may be a mechanism of biological importance contributing to the anti-tumour effect of AG. This possibility merits investigation in future trials.
